Cargando…

Value of immune factors for monitoring risk of lung cancer in patients with interstitial lung disease

OBJECTIVE: Patients with interstitial lung disease (ILD) are at increased risk of developing lung cancer. We aimed to investigate the clinical significance of serum immune factors in this progression. METHODS: We retrospectively screened a hospital database from January 2012 to December 2016 for pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ning, Hu, Haisheng, Wu, Ge, Sun, Baoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683915/
https://www.ncbi.nlm.nih.gov/pubmed/31256734
http://dx.doi.org/10.1177/0300060519847403
_version_ 1783442182734086144
author Li, Ning
Hu, Haisheng
Wu, Ge
Sun, Baoqing
author_facet Li, Ning
Hu, Haisheng
Wu, Ge
Sun, Baoqing
author_sort Li, Ning
collection PubMed
description OBJECTIVE: Patients with interstitial lung disease (ILD) are at increased risk of developing lung cancer. We aimed to investigate the clinical significance of serum immune factors in this progression. METHODS: We retrospectively screened a hospital database from January 2012 to December 2016 for patients with lung cancer and ILD. We measured serum levels of C3, C4, IgA, IgG, IgM, C-reactive protein (CRP), ceruloplasmin (CER), and rheumatoid factor in these patients and in healthy controls. RESULTS: We analyzed data for 262 patients with lung cancer, 220 with ILD, and 57 healthy controls. CER levels were significantly higher in patients with lung cancer (0.35 ± 0.10 g/L) compared with both ILD patients (0.31 ± 0.25 g/L) and healthy individuals (0.25 ± 0.04 g/L). C3 and C4 levels were both significantly higher in healthy individuals compared with patients with lung cancer (C3: 1.70 ± 0.29 vs 1.04 ± 0.26 g/L, C4: 0.27 ± 0.24 vs 0.24 ± 0.09 g/L) and ILD (C3: 1.70 ± 0.29 vs 0.97 ± 0.25 g/L, C4: 0.27 ± 0.24 vs 0.21 ± 0.09 g/L). Optimal scaling analysis demonstrated that lung cancer was closely associated with CRP, CER, C3, and C4. CONCLUSIONS: Increased levels of CRP and CER and decreased levels of C3 and C4 may identify patients with ILD at high risk of developing lung cancer.
format Online
Article
Text
id pubmed-6683915
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-66839152019-08-19 Value of immune factors for monitoring risk of lung cancer in patients with interstitial lung disease Li, Ning Hu, Haisheng Wu, Ge Sun, Baoqing J Int Med Res Pre-Clinical Research Reports OBJECTIVE: Patients with interstitial lung disease (ILD) are at increased risk of developing lung cancer. We aimed to investigate the clinical significance of serum immune factors in this progression. METHODS: We retrospectively screened a hospital database from January 2012 to December 2016 for patients with lung cancer and ILD. We measured serum levels of C3, C4, IgA, IgG, IgM, C-reactive protein (CRP), ceruloplasmin (CER), and rheumatoid factor in these patients and in healthy controls. RESULTS: We analyzed data for 262 patients with lung cancer, 220 with ILD, and 57 healthy controls. CER levels were significantly higher in patients with lung cancer (0.35 ± 0.10 g/L) compared with both ILD patients (0.31 ± 0.25 g/L) and healthy individuals (0.25 ± 0.04 g/L). C3 and C4 levels were both significantly higher in healthy individuals compared with patients with lung cancer (C3: 1.70 ± 0.29 vs 1.04 ± 0.26 g/L, C4: 0.27 ± 0.24 vs 0.24 ± 0.09 g/L) and ILD (C3: 1.70 ± 0.29 vs 0.97 ± 0.25 g/L, C4: 0.27 ± 0.24 vs 0.21 ± 0.09 g/L). Optimal scaling analysis demonstrated that lung cancer was closely associated with CRP, CER, C3, and C4. CONCLUSIONS: Increased levels of CRP and CER and decreased levels of C3 and C4 may identify patients with ILD at high risk of developing lung cancer. SAGE Publications 2019-07-01 2019-07 /pmc/articles/PMC6683915/ /pubmed/31256734 http://dx.doi.org/10.1177/0300060519847403 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Pre-Clinical Research Reports
Li, Ning
Hu, Haisheng
Wu, Ge
Sun, Baoqing
Value of immune factors for monitoring risk of lung cancer in patients with interstitial lung disease
title Value of immune factors for monitoring risk of lung cancer in patients with interstitial lung disease
title_full Value of immune factors for monitoring risk of lung cancer in patients with interstitial lung disease
title_fullStr Value of immune factors for monitoring risk of lung cancer in patients with interstitial lung disease
title_full_unstemmed Value of immune factors for monitoring risk of lung cancer in patients with interstitial lung disease
title_short Value of immune factors for monitoring risk of lung cancer in patients with interstitial lung disease
title_sort value of immune factors for monitoring risk of lung cancer in patients with interstitial lung disease
topic Pre-Clinical Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683915/
https://www.ncbi.nlm.nih.gov/pubmed/31256734
http://dx.doi.org/10.1177/0300060519847403
work_keys_str_mv AT lining valueofimmunefactorsformonitoringriskoflungcancerinpatientswithinterstitiallungdisease
AT huhaisheng valueofimmunefactorsformonitoringriskoflungcancerinpatientswithinterstitiallungdisease
AT wuge valueofimmunefactorsformonitoringriskoflungcancerinpatientswithinterstitiallungdisease
AT sunbaoqing valueofimmunefactorsformonitoringriskoflungcancerinpatientswithinterstitiallungdisease